Overview

A Phase 1b Study to Assess the Safety and Anti-inflammatory Effects of Two Different Doses of SRT2104 in Patients With Ulcerative Colitis

Status:
Completed

Trial end date:
2013-03-18

Target enrollment:

Participant gender:

Summary

The purpose of this research study is to: - 1) Test the safety and tolerability of 2 different oral doses of SRT2104 in subjects with ulcerative colitis - 2) Determine the amount of SRT2104 measured from a single blood sample in addition to colon and/or rectal tissue samples (biopsies) - 3) Determine whether SRT2104 has any anti-inflammatory effect on the colon and/or rectum when taken orally for 8 weeks - 4) Determine whether SRT2104 causes any detectable changes to specific biomarkers. A biomarker is a biological marker (or substance such as a protein) that is used as an indicator of changes in a biological state that corresponds to the risk or progression of a disease.

Phase:

Phase 1

Details

Lead Sponsor:

Sirtris, a GSK Company

Collaborator:

GlaxoSmithKline

Treatments:

Anti-Inflammatory Agents